AGREEMENT AND PLAN OF MERGER by and among NOVARTIS AG,Agreement and Plan of Merger • June 6th, 2000 • Novartis Inc • Ophthalmic goods • Delaware
1 AGREEMENT JOINT FILING OF SCHEDULE 13G1 Agreement • February 14th, 1997 • Novartis Inc • Pharmaceutical preparations
CONFORMED COPY AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • January 17th, 1997 • Novartis Inc • Services-commercial physical & biological research • New York
Joint Filing AgreementJoint Filing Agreement • February 12th, 2021 • Novartis Pharma Ag • Biological products, (no disgnostic substances)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing Agreement PURSUANT TO RULE 13d-1(k)Joint Filing Agreement • August 14th, 2020 • Novartis Pharma Ag • Biological products, (no disgnostic substances)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he, she or it knows that such information is inaccurate.
ROLLOVER AND SUPPORT AGREEMENT August 11, 2020Rollover and Support Agreement • August 14th, 2020 • Novartis Pharma Ag • Biological products, (no disgnostic substances) • Delaware
This ROLLOVER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of the date set forth above by and among CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Parent”), and the undersigned stockholder of Cellular Biomedicine Group, Inc., a Delaware corporation (the “Company”) listed on Schedule A hereto (“Rollover Stockholder”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).
Joint Filing AgreementJoint Filing Agreement • December 19th, 2022 • Novartis Pharma Ag • Pharmaceutical preparations
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
WAIVER August 11, 2020August 11, 2020 • August 14th, 2020 • Novartis Pharma Ag • Biological products, (no disgnostic substances) • Delaware
THIS WAIVER (this “Waiver”) is made with reference to the License and Collaboration Agreement dated September 25, 2018 (the “License Agreement”) by and among Novartis Pharma AG, a company (Aktiengesellschaft) organized and existing under the laws of Switzerland (“Novartis”), Cellular Biomedicine Group, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), and certain of the Company’s subsidiaries as parties thereto (such subsidiaries and the Company collectively, “CBMG”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. This Waiver is given by Novartis on the date set forth above (the “Waiver Effective Date”) in connection with the Merger (defined below).
May 10, 2000Novartis Inc • June 6th, 2000 • Ophthalmic goods
In connection with discussions between Wesley Jessen VisionCare, Inc. ("WJ") and CIBA Vision Corporation ("CIBA") regarding the possibility of entering into a business transaction with each other, each of us may need to review certain of the other party's non-public information regarding such party. As a condition for the disclosure of such information to each other, WJ and CIBA each agree, as set forth below, to treat confidentially all such information, all materials containing such information which the disclosing party or its directors, officers, employees, affiliates, prospective capital or financing sources, advisors or other representatives (hereinafter referred to collectively as a party's "Representatives") furnish or cause to be furnished, and all materials prepared by the disclosing party or its Representatives using, incorporating or relating to such information (collectively, such information and materials are referred to hereinafter as that party's "Information and Evalua
Joint Filing AgreementJoint Filing Agreement • June 27th, 2022 • Novartis Pharma Ag • Biological products, (no disgnostic substances)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
Joint Filing AgreementJoint Filing Agreement • October 8th, 2021 • Novartis Pharma Ag • Services-commercial physical & biological research
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
WAIVER August 11, 2020August 11, 2020 • August 14th, 2020 • Novartis Pharma Ag • Biological products, (no disgnostic substances) • Delaware
THIS WAIVER (this “Waiver”) is made with reference to the Toll Manufacturing and Supply Agreement dated December 21, 2018 (the “Supply Agreement”) by and among Novartis Pharma AG, a company (Aktiengesellschaft) organized and existing under the laws of Switzerland (“Novartis AG”), Beijing Novartis Pharma Co., Ltd., a company organized and existing under the laws of the People’s Republic of China (“Novartis China” together with Novartis AG, “Novartis”), Cellular Biomedicine Group, Inc., a corporation organized and existing under the laws of Delaware, (the “Company”), and Shanghai Cellular Biopharmaceutical Group Ltd., a company organized and existing under the laws of the People’s Republic of China (“CBMG China”, together with the Company, “CBMG”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Supply Agreement. This Waiver is given by Novartis on the date set forth above (the “Waiver Effective Date”) in connection with the Merger (defined b
JOINT FILING AGREEMENTJoint Filing Agreement • November 8th, 2018 • Novartis Pharma Ag • Biological products, (no disgnostic substances)
The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the timely filing of such statement on Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness or accuracy of the information concerning the others of the undersigned, except to the extent that it knows or has reason to believe that such information is inaccurate or incomplete. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
